 | Hi Renukaprasad A R, | | Are you aware of the nanotechnology-based advancements in DED management? | Artificial tears are the primary treatment option for DED because they help with symptomatic relief. However, conventional formulations have poor bioavailability due to the complex ophthalmic structure and rapid tear turnover. Nanotechnology has the solution to this limitation.
Here is an article on the overview of nanotechnology with particular emphasis on its application in ophthalmology and DED. | Highlights -
- A brief overview of nanotechnology
- Different types of nanosystems
- Introduction to lipid-based nanocarriers (LNCs)
- Applications of LNCs
| | | | | | | | If you don't want to receive these emails in the future, please unsubscribe. | | | | |
.gif "add docplexus to primary")
No comments:
Post a Comment